2014年美国第50届临床肿瘤年会乳腺癌内科治疗热点撷英  

Highlights Top Stories from 2014 (the 50th) Annual Meeting of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in Medical Therapy

作　　者：严颖[1] 李惠平[1] YAN Ying;LI Hui-ping(Department of Breast Oncology,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺内科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《临床药物治疗杂志》2014年第S01期1-5,共5页Clinical Medication Journal

摘　　要：2014年美国临床肿瘤年会(ASCO)在芝加哥召开,大会报告了乳腺癌领域重要的基础研究成果和临床研究数据。本文主要综述了乳腺癌内科治疗领域4项主要临床研究结果:①与他莫西芬+卵巢功能抑制相比,依西美坦+卵巢功能抑制也可以用于激素受体阳性的绝经前早期乳腺癌,但年轻患者要充分做到卵巢功能抑制。②在辅助曲妥珠单抗治疗的基础上联合拉帕替尼没有获得改善HER2阳性乳腺癌的预后。③贝伐珠单抗联合化疗辅助治疗HER2阴性乳腺癌没有获得总生存的改善。④依西美坦+贝伐珠单抗用于转移性乳腺癌维持治疗在治疗周期上有一定延长。本文对乳腺癌内科治疗的进展进行了综述报道。The 2014 American Society of Clinical Oncology(ASCO)Annual Meeting held in Chicago,provided a comprehensive review of key experimental and clinical data and provided an opportunity for researchers from around the world to present their research in a variety of breast cancer ifelds.The folowing section provides brief summaries of some of the most interesting work involving four major medical therapy studies.①Adjuvant exemestane combined with ovarian function suppression is another choice in premenopausal patients with hormone receptor positive,but ovarian function should be completely inhibited.②Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive Breast Cancer.③Adding bevacizumab to adjuvant chemotherapy does not improve survival outcomes in patients with HER2 negative breast cancer.④Exemestane+bevacizumab maintenance therapy for metastatic breast cancer get longer therapeutic period,but not survival beniift.This review highlights the medical treatment for patients with breast cancer.

关 键 词：乳腺癌 内科治疗 热点 

分 类 号：R978.7[医药卫生—药品] R512.62[医药卫生—药学]